Summary
Amgen Inc. (AMGN) filed an 8-K on November 2, 2017, to report a material definitive agreement related to a debt issuance. The Company issued and sold $1 billion of 3.200% Senior Notes due 2027. The net proceeds from this offering are approximately $990.4 million, after accounting for underwriting discounts and estimated offering expenses. These notes are a component of Amgen's broader financing strategy and are registered under a previously filed Form S-3. The issuance aims to strengthen the company's financial position and potentially fund ongoing operations and strategic initiatives. Key terms of the Notes include a maturity date of November 2, 2027, and semi-annual interest payments of 3.200% per annum, paid on May 2 and November 2, starting May 2, 2018. A significant provision is the change in control clause, which allows noteholders to require Amgen to repurchase their notes at 101% of the principal amount plus accrued interest in the event of a specified change in control triggering event. Investors should note that these senior notes rank equally with existing and future senior unsecured debt but are subordinated to the obligations of Amgen's subsidiaries and any secured obligations.
Key Highlights
- 1Amgen Inc. issued $1 billion in 3.200% Senior Notes due 2027.
- 2Net proceeds from the offering amounted to approximately $990.4 million.
- 3The Notes mature on November 2, 2027, with semi-annual interest payments.
- 4A change in control provision allows noteholders to demand repurchase at 101% of principal plus interest.
- 5The Notes rank pari passu with existing and future senior unsecured indebtedness.
- 6The issuance was registered under a previously filed Form S-3.
- 7The filing also includes the computation of Amgen's ratio of earnings to fixed charges.